AI Article Synopsis
- Oral mucositis (OM) is a common side effect of chemotherapy, often diagnosed based on patient reports, and this study aimed to create a more accurate diagnostic tool.
- A central review system (CRS) was implemented to evaluate OM without prior patient background knowledge, comparing it to individual clinician assessments from four institutions.
- Results showed the CRS identified OM in 84.9% of patients, significantly higher than the 41.5% detection rate by clinicians, highlighting that OM may be frequently underestimated in chemotherapy patients.
Article Abstract
Background/aim: Oral mucositis (OM) is one of the frequent adverse events experienced by patients receiving chemotherapy. Most diagnoses of OM are based on complaints from patients. The aim of this study was to develop a tool to diagnose OM accurately.
Materials And Methods: A central review system (CRS) was created to allow judgment when the patient background is completely unknown. The primary endpoint was the rate of grade 2 or higher OM, and the secondary endpoint was the difference in grade between each institution's clinician judgement and that of the CRS.
Results: In total, 53 patients were registered from four institutions. CRS successfully detected grade 2 or higher OM in 16 (30.2%) of the 53 patients. The detection rate of all grades of OM was 41.5% (22 of 53 patients) by each institution's clinician judgement and 84.9% (45 of 53 patients) by CRS judgement (p<0.0001).
Conclusion: OM during chemotherapy may be underestimated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.13616 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!